Truist analyst Danielle Brill initiated coverage of Neurocrine (NBIX) with a Buy rating and $163 price target Despite headwinds in the marketplace, the firm is “confident” in the outlook for the base Ingrezza business and views the Crenessity launch as the key growth driver over the next 12-plus months, the analyst tells investors. In addition, the remaining pipeline is “high-risk,” but all potential upside to the firm’s model, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences’ NBI-921352 Study: A Potential Game-Changer for SCN8A-DEE Treatment
- Neurocrine Biosciences’ NBI-921352 Study Update: Implications and Insights
- Neurocrine’s Growth Potential Driven by Ingrezza’s Market Share and Crenessity’s Uptake
- Neurocrine presents one-year data from study of Crenessity
- Neurocrine Biosciences’ Phase 2 Study on NBI-1117568 for Schizophrenia: Key Updates